Shanghai Chest Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: -

Established: 1957-01-01

Employees: -

Market Cap: -

Website: http://www.shmtppp.com/hospitals/chest

Clinical Trials

Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer

Conditions: Esophageal Cancer

First Posted Date: 2021-07-30

Last Posted Date: 2021-07-30

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 50

Registration Number: NCT04984096

Analysis of Drug Resistance in Immune Checkpoint Inhibitors of Non-small Cell Lung Cancer

Recruiting

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2021-07-27

Last Posted Date: 2024-04-17

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 250

Registration Number: NCT04977791

Locations: 🇨🇳
Xiaomin Niu, Shanghai, Shanghai, China

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Trametinib
Drug: Anlotinib

First Posted Date: 2021-07-19

Last Posted Date: 2024-04-23

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 33

Registration Number: NCT04967079

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Termination of Persistent Atrial Fibrillation by Catheter Ablation

Conditions: Atrial Fibrillation

Interventions: Procedure: Catheter ablation

First Posted Date: 2021-07-12

Last Posted Date: 2021-07-12

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 400

Registration Number: NCT04958928

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Phase 2

Recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Furmonertinib
Drug: Anlotinib

First Posted Date: 2021-05-20

Last Posted Date: 2023-01-06

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 40

Registration Number: NCT04895930

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Phase 2

Conditions: Lung Cancer
EGFR Gene Mutation

Interventions: Drug: Almonertinib

First Posted Date: 2021-05-11

Last Posted Date: 2021-05-11

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 40

Registration Number: NCT04882345

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Phase 3

Conditions: NSCLC

Interventions: Drug: Osimertinib
Drug: Almonertinib

First Posted Date: 2021-05-03

Last Posted Date: 2021-05-03

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 232

Registration Number: NCT04870190

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Phase 4

Conditions: NRG1-fused Non-small Cell Lung Cancer

Interventions: Drug: Afatinib Dimaleate

First Posted Date: 2021-03-24

Last Posted Date: 2021-04-01

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 15

Registration Number: NCT04814056

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Phase 1

Completed

Conditions: Locally Advanced Solid Tumor
Non-Small Cell Lung Cancer With EGFR Mutation
Metastatic Cancer
Adenocarcinoma of Lung

Interventions: Drug: Osimertinib
Drug: Anlotinib

First Posted Date: 2021-02-25

Last Posted Date: 2024-08-15

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 25

Registration Number: NCT04770688

Locations: 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China

ENB-guided Ablation Therapy Combined With VATS in the Treatment of MPLC

Recruiting

Conditions: Lung Cancer

First Posted Date: 2021-01-29

Last Posted Date: 2021-01-29

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 30

Registration Number: NCT04730453

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy